Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Passes Above 50 Day Moving Average - Here's Why

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report)'s stock price passed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $3.26 and traded as high as $3.35. Oramed Pharmaceuticals shares last traded at $3.31, with a volume of 368,355 shares trading hands.Get Oramed Pharmaceuticals alerts:Wall Street Analyst Weigh InA number of equities analysts have recently weighed in on ORMP shares. Weiss Ratings reiterated a "hold (c)" rating on shares of Oramed Pharmaceuticals in a report on Monday, December 29th. Wall Street Zen raised shares of Oramed Pharmaceuticals to a "hold" rating in a research note on Saturday, November 1st. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the company presently has a consensus rating of "Hold".Read Our Latest Stock Analysis on ORMPOramed Pharmaceuticals Price PerformanceThe company's 50 day moving average price is $3.26 and its 200 day moving average price is $2.71. The firm has a market cap of $131.74 million, a PE ratio of 2.63 and a beta of 1.34. Oramed Pharmaceuticals Announces DividendThe business also recently disclosed a dividend, which was paid on Monday, January 26th. Stockholders of record on Friday, January 16th were given a dividend of $0.25 per share. The ex-dividend date of this dividend was Friday, January 16th. Oramed Pharmaceuticals's dividend payout ratio is currently 19.84%. Institutional Inflows and OutflowsSeveral institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE raised its position in Oramed Pharmaceuticals by 4.4% in the 3rd quarter. Bank of America Corp DE now owns 149,667 shares of the biotechnology company's stock valued at $395,000 after purchasing an additional 6,261 shares in the last quarter. XTX Topco Ltd increased its stake in shares of Oramed Pharmaceuticals by 59.9% during the fourth quarter. XTX Topco Ltd now owns 38,182 shares of the biotechnology company's stock worth $109,000 after buying an additional 14,297 shares during the period. Jane Street Group LLC raised its holdings in Oramed Pharmaceuticals by 35.3% in the first quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company's stock valued at $144,000 after acquiring an additional 17,510 shares in the last quarter. Squarepoint Ops LLC lifted its stake in Oramed Pharmaceuticals by 95.1% in the fourth quarter. Squarepoint Ops LLC now owns 58,272 shares of the biotechnology company's stock worth $166,000 after acquiring an additional 28,406 shares during the last quarter. Finally, Quadrature Capital Ltd acquired a new position in Oramed Pharmaceuticals during the 4th quarter worth approximately $119,000. 12.73% of the stock is owned by institutional investors and hedge funds. Oramed Pharmaceuticals Company Profile (Get Free Report)Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed's platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery. The company's lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.Further ReadingFive stocks we like better than Oramed PharmaceuticalsElon Musk already made me a “wealthy man”Elon’s Secret AI Partner?Silver $500? The "Deficit Math" says it's possible.Elon Musk: This Could Turn $100 into $100,000Buffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Oramed Pharmaceuticals Right Now?Before you consider Oramed Pharmaceuticals, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oramed Pharmaceuticals wasn't on the list.While Oramed Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here